Meda: Strategic Acquisition of MedPointe Inc Completed
`
`• Acquisition of MedPointe has now been completed.
`• Meda enters the US market and becomes a world-class specialty pharma company
`with sales of around 9 billion SEK.
`• Final purchase price of MedPointe was 5 229 MSEK.
`
`August 22, 2007 02:13 AM Eastern Daylight Time
`
`STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
`
`On 20 July 2007, Meda (STO:MEDAA) announced that it had signed an agreement to acquire all shares in MedPointe.
`This strategic acquisition has now been completed and consolidation of MedPointe starts immediately. Meda plans to give
`further information on the acquisition and its impact on Meda in the interim report for the third quarter – to be released on
`30 October 2007.
`
`The final purchase price for MedPointe was 5 229 MSEK. This price consisted of 520 MUSD in cash and 17,5 million
`newly issued Meda shares. The cash component of 520 MUSD was hedged at SEK/USD 6,74 and compared to the
`current exchange rate this is equivalent to a positive effect of about 100 MSEK. The cash payment was therefore 3 506
`MSEK, an amount fully financed through an existing credit facility. The book value of the newly issued shares was set to
`98,50 SEK per share. New shareholders in Meda are The Carlyle Group, The Cypress Group LLC, and other US investors,
`who will have a combined shareholding in Meda of approximately 7%.
`
`The strategic acquisition of MedPointe will establish Meda as a world-class specialty pharma company with full marketing
`coverage both in the US and Europe and with revenues of around 9 billion SEK. The acquisition of MedPointe is expected
`to be accretive to Meda’s earnings per share at the latest during 2009.
`
`MedPointe is a fast growing US-based specialty pharma company focused on two of Meda’s priority areas, Allergy /
`Respiratory and Pain. The product portfolios are highly complementary. MedPointe’s net sales in 2006 were 252 MUSD,
`representing a 23% growth in local currency compared to previous year. Net sales for the first half of 2007 amounted to
`around 145 MUSD, which, on an annualised basis, is equivalent to a purchase price revenue multiple of around 2,6. On a
`pro forma basis, Meda’s US operation accounts for about 20% of annual sales. Meda’s pipeline which is open for the US
`market can now be commercialised in own regimen through a wholly-owned subsidiary and thereby retaining 100% of the
`value of the product assets. Likewise Meda, through its strong European organisation, will be able to capitalise on product
`development opportunities based on MedPointe’s pipeline. The new transatlantic combination will enable Meda to develop
`synergies both as to geographical markets and product portfolios.
`
`MEDA AB (publ) is an international specialty pharma company that concentrates on marketing and market-adapted
`product development. Acquisitions and long-term partnerships are fundamental factors that drive the company’s strategy.
`Meda is represented with own organisations 26 countries and with more than 1 500 employees within marketing and sales.
`Meda’s products are sold in approximately 120 countries world-wide. The Meda share is listed under Large Cap on the
`OMX Nordic Stock Exchange. Find out more, visit www.meda.se.
`Exhibit 1057
`IPR2017-00807
`ARGENTUM
`
`This information was brought to you by Cision http://newsroom.cision.com
`
`000001
`
`

`

`Contacts
`Meda
`Anders Larnholt
`Investor Relations
`tel. +46 8 630 19 62, +46 709 458 878
`
`000002
`
`